loading...
Distributed by Mapi Research Trust
Distributed by Mapi Research Trust
WEBINAR: An Author Webinar on the ABOUT™—Perceived Risk - Recorded session available here!
Data regarding development and initial validation studies have been published in peer-reviewed journals. The original name of the instrument was Perceived Risk Instrument (PRI), Personal version (PRI-P) and General version (PRI-G). The name was changed later to ABOUT™—Perceived Risk. The acronym PRI is kept in the description of the measurement properties to respect the original reference.
There are 2 versions of the ABOUT™—Perceived Risk, an original version of 18 items and a short version of 9 items.
Background:
Philip Morris has launched an ongoing collaborative effort to develop fit-for-purpose measurement instruments (i.e., concept-driven instruments providing interpretable outcomes for the purpose intended) to enhance the scientific framework of harm reduction. This new initiative has resulted in the creation of the ABOUT™ Toolbox (Assessment of Behavioral OUtcomes related to Tobacco and nicotine products).
The ABOUT™ Toolbox currently comprises five measurement instruments that are at various stages of development and validation
The ABOUT™—Perceived Risk has been developed as a self-report instrument designed to assess the perceived risks associated with the use of tobacco and nicotine-containing products, including Conventional Cigarettes (CCs), Nicotine Replacement Therapy products (NRTs), and Reduced Risk Products (RRPs*). The ABOUT™—Perceived Risk can also be used to assess the perceived risks associated with the past use of CC (e.g., ‘Cessation’).
By quantifying perceived tobacco and nicotine-containing product risks, the ABOUT™—Perceived Risk may be used by researchers in clinical and population-based studies to gather meaningful insight on 1) the effects of risk perception on tobacco and nicotine-containing product use behavior among current tobacco users, 2) the effects on product use initiation among non-users, and 3) the effects of risk communication on consumers’ understanding and perceptions.
The ABOUT™—Perceived Risk has been developed to assess two sets of perceptions:
1) the perceived risks to the individual respondent (personal risk);
and
2) the perceived risks to users of the product in general (general risk).
The two versions share the same items and response options; only the opening stems differ so that it orients respondents to respond with regards to their personal risk or the risks to the average user of the product.
* Reduced-Risk Products (“RRPs”) is the term PMI S.A. use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. PMI S.A. has a range of RRPs in various stages of development, scientific assessment and commercialization. Because RRPs do not burn tobacco, they produce far lower quantities of harmful and potentially harmful compounds than found in cigarette smoke.
More details are available on www.pmiscience.com
Philip Morris Products S.A.
Cano S, Chrea C, Salzberger T, Alfieri T, Emilien G, Mainy N, Ramazzotti A, Lüdicke F, Weitkunat R. Development and validation of a new instrument to measure perceived risks associated with the use of tobacco and nicotine-containing products. Health Qual Life Outcomes. 2018 Sep 21;16(1):192 (Full Text Article)
Salzberger T, Chrea C, Cano S, Martin M, Atkison M, Emilien G, Mainy N, Ramazzotti A, Weitkunat R, Lüdicke F. Perceived risks associated with the use of tobacco and nicotine-containing products: Findings from qualitative research. Tobacco Science & Technology. 2017 Dec; 50(13): 32-42 (Full Text Article)
Philip Morris Products S.A.
Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66
You may access the questionnaire and/or its available translations directly (see tutorial). Should you not see the Download button, please contact us.
Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.
Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.
The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.
Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.
The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.
For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).
If you wish to translate the questionnaire:
Access to advanced descriptions of Clinical Outcome Assessments (COAs)